How Often to Take BPC-157 — Daily vs Weekly Dosing

Individuals yearning for BPC-157 dosing frequency are not looking for long explanations – they want to know if the treatment is taken once daily, twice daily, or in another frequency. The literature gives only one concrete information while keeping everything else vague. The published studies show that in almost every experiment the subjects were given the drug each day. There are no comparative studies that would differentiate between daily and weekly dosing or studies that would research the timing of administration of the compound.

How Often Was BPC-157 Given in Published Studies

Daily Administration Was the Standard

In studies about BPC-157, the treatment was commonly given once a day. Staresinic et al. (2003) used this method, giving 10 mcg/kg IP daily for 2 weeks to subjects in their Achilles tendon study (PMID 14554208). The same once-daily administration of BPC-157 was done by Cerovecki et al. (2010) for the duration of their study (PMID 20225319). In addition, Brcic et al. (2009) follow BPC-157 once daily in their muscle crush experiment (PMID 20388964).

The fact that studies produce similar results does not prove that giving the dose once a day is the best option. This phenomenon, however, does demonstrate the practical convention in the field of rodent drug research, which is that daily administration via injection is considered an easy, repeatable, and normal practice.

Twice-Daily Dosing in Some GI Models

Few researchers conducted studies using the twice-daily mode of administration. In their experiments on the treatment of ulcers, Sikiric et al.(1993) used several modes of administration, among others. Some experimental procedures aimed at exploring gastroprotective effects of drugs employed protocols of repeated dose in order to keep peptides in the digestive system (PMID 8298609). The models based on administration of peptides via drinking water reviewed by Sikiric et al. (2018) showed that continuous administration was possible in these experimental protocols since animals consumed water all day long (PMID 29879879).

The few examples of dosage given twice a day were based on specific needs of the gastrointestinal model, rather than any pharmacokinetics-related considerations. No specific studies were conducted that directly assessed the comparative effects of administering a therapeutic agent once or twice daily, using the same total dose.

Daily vs Weekly - What Was Actually Tested

No Study Compared Daily to Weekly Dosing

We have conducted a review of the BPC-157 literature, and it was discovered that there are no studies regarding different dosing intervals. There are also no experiments for comparing daily with every other day, twice a week, and weekly dose administration schedules. There is no literature answering the question whether infrequent administration will be effective.

There is clearly a gap here. In other peptide medicine areas, the dosage schedule is important to outcomes. Some peptides must be given weekly, while others have to be administered daily or even with double dosage. Without comparative frequency information for BPC-157, we are simply unaware of its spot on the scale.

Why the Question Exists Despite No Data

Questions regarding the frequency of dosing arise from the fact that it affects matters like ease of use, cost and the burden of the administration of the drug. If it were not the case, people would use weekly medications instead of daily ones. There are various recommendations in forums with dosage mentioned, ranging from every day to two times per day to every time it is needed. None of those recommendations apparently was the subject of testing in real life. All in all, it is a valid question but there is no definite answer in this regard yet.

BPC-157 Half-Life - What Limited Data Suggests

Peptide Pharmacokinetics in Small Molecules

Peptides that are about the same size as BPC-157 (15 amino acids) are usually found to have short plasma half-lives of just a few minutes to several hours. Small peptides are quickly removed from circulation due to the actions of the kidneys and acts of enzymes. If BPC-157 behaves similarly as expected, this justifies daily dosage or even more often to keep the tissue well exposed.

Nonetheless, BPC-157 has some uncommon characteristics. As stated by the Sikiric team, BPC-157 is unique in that it remains stable in the digestion environment and intolerant to some types of degradation (PMID 29879879). However, whether this trait applies to the half-life in the blood plasma is yet to be determined.

No Human PK Data Published for BPC-157

Pharmacokinetic (PK) data explain how a compound gets into the body, moves around, is metabolized, and is expelled. For BPC-157, such data is not available for human studies. So far, we are not aware of any research studying the effect of BPC-157 on plasma concentrations over time. Hence, we have no idea about the physicochemical parameters such as half-life, maximum concentration time, or elimination rate.

In the absence of pharmacokinetic data, suggestions regarding how frequently to administer a compound rely primarily on extrapolation from generic peptide pharmacology or empirical studies conducted in animals at daily dosing. Yet, neither is a surrogate for direct measurement.

What Frequency Data Does Not Tell Us

Optimal Timing Not Established

Timing is as important as frequency. Is it better to take the drug with the meals, when physically active, or while sleeping? Should it be taken in the morning or at night? There is no study of BPC-157 that has analyzed timing as a variable. The studies that were done on rats gave the peptide consistently in due course not because time is important.

Specific pharmacological logics apply to injectable peptides characterized by brief half-lives; this fact gives rise to the conclusion that timing with respect to the desired effect is critical in these cases. However, this statement cannot be applied to BPC-157.

Accumulation and Washout Unknown

When it comes to administering a substance on a daily basis, one of the questions that arise is whether the substance accumulates in the tissues over time or is completely cleared before taking the next dose. In our experience with once-daily IP dosing in rats, we do not know if BPC-157 levels keep on accumulating or whether they stay constant. The answer to this question affects our opinion on frequency of administration. In the case of peptide accumulating in the tissues, less frequent administration may provide the same levels in the tissues that would be achievable with daily administration. If the peptide is cleared quickly, however, its daily or more frequent dosing would be required in order to keep the exposure constant.

Sikiric et al. (2010) reviewed the BPC-157 literature and noted the absence of toxicity findings, which could indirectly suggest that accumulation to toxic levels did not occur at the doses tested (PMID 20166993). But the absence of observed toxicity does not tell us about accumulation patterns.